DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SUPRIYA LIFESCIENCE LTD (SUPRIYA) share price today?

SUPRIYA LIFESCIENCE LTD (SUPRIYA) is trading at ₹828.7 on the NSE, down 2.57% on the day. Source: DocStoX.

What is the PE ratio of SUPRIYA LIFESCIENCE LTD?

SUPRIYA LIFESCIENCE LTD has a price-to-earnings (PE) ratio of 35.5 in the Healthcare sector.

What is the market capitalisation of SUPRIYA LIFESCIENCE LTD?

SUPRIYA LIFESCIENCE LTD has a market capitalisation of approximately ₹6,672 crore.

SUPRIYA LIFESCIENCE LTD

SUPRIYA·NSE·Healthcare

₹828.70▼ -21.90 (-2.57%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

Day₹816.10

₹850.60

52W₹546

₹108552%

Open

₹850.60

High

₹850.60

Low

₹816.10

Prev Close

₹850.60

Volume

2.66L

VWAP

₹825.64

Snapshot

Key fundamentals

Market Cap

₹6,672 Cr

P/E Ratio

35.49Expensive

P/B Ratio

5.88

EPS

₹23.35

Book Value

₹148.82

ROE

18.86%Strong

ROCE

27.00%Efficient

Dividend Yield

0.11%

Debt / Equity

0.00Low

Face Value

₹2.00

52W High

₹1085.00

52W Low

₹545.50

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹221

▼ 73.3%downside

Trading at ₹829 — 73% above our estimate

BearFair valueBull

₹188₹221₹280

/100

Business quality — Solid

Growth 0Profitability 85Efficiency 48Valuation 68

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 3/9)

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 27%)
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

19% ROE fading to 12% over ~10 yrs, on ₹149 book

₹205

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹280

Analyst target

No analyst coverage

—

Blended fair value₹221

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 27%)
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

35.5Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

18.9%Strong

Above 15% is considered healthy for Indian equities

ROCE

27.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹6,672 Cr

P/B

5.88

EPS

₹23.35

Div Yield

0.11%

What changed

Recent changes

Domestic institutions+0.7% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 35.5×

Growth

Strong

+22% rev CAGR

Profitability

Excellent

18.9% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %43.1%

Turnover₹2197.02L Cr

Trades13,672

VWAP₹825.64

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+21.6%

+16.2%

10Y

—

Profit

+32.5%

+11.0%

10Y

—

EPS

—

10Y

—

Profile

Pros

Company is almost debt free.
Company is expected to give good quarter

Watch-outs

Cons

Debtor days have increased from 79.6 to 96.8 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Domestic institutions added 0.69 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

68%

Promoter

Promoters

68.3%0.00

Public

16.2%-0.44

FII / FPI

5.2%-0.04

DII

5.7%+0.69

Others

4.6%

Total shareholders

81,161-3,938 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter68.30%

FII5.16%

DII5.70%

Public16.22%

Others4.62%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions